TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20346136

Group type: EXPERIMENTAL
Intervention: Standard of care plus mobile phone reminders (automated call and picture message, delivered once a week)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 600
Study: 17537764

Group type: EXPERIMENTAL
Intervention: 250 mg daily azithromycin
Number of subjects: 208

Group type: COMPARATOR
Intervention: 1,200 mg weekly azithromycin
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 250 mg daily azithromycin (in patients aged <18 yrs)
Number of subjects: 208

Group type: COMPARATOR
Intervention: 1,200 mg weekly azithromycin (in children)
Number of subjects: 208
Study: 16214597

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 90056
Study: 11684377

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CA) 10 mg/day
Number of subjects: 336

Group type: COMPARATOR
Intervention: Micronized progesterone (P) 200 mg/day
Number of subjects: 336
Study: 9455602

Group type: EXPERIMENTAL
Intervention: Benign Focal Epilepsy of Childhood with Occipital Paroxysms (BEOP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Symptomatic occipital lobe epilepsy
Number of subjects: 11
Study: 8187108

Group type: COMPARATOR
Intervention: Transdermal nitroglycerin (NTG) - acute administration (2 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) - continuous administration (24 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) - intermittent administration (24 days)
Number of subjects: 10
Study: 3370064

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 6

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 6
Study: 31373899

Group type: EXPERIMENTAL
Intervention: New reference values for sonographic estimated fetal weight (sEFW) in twin gestations
Number of subjects: 195

Group type: COMPARATOR
Intervention: Comparison to previously published sEFW normograms for twin gestations
Number of subjects: 195
Study: 27736248

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (NIT) - 70 mL of beetroot juice containing 4 mmol NO3‐ for 8 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA) - NO3‐-depleted placebo for 8 days
Number of subjects: 8
Study: 25028991

Group type: EXPERIMENTAL
Intervention: Endurance training followed by strength (ES)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Strength training followed by endurance (SE)
Number of subjects: 14
Study: 24150466

Group type: EXPERIMENTAL
Intervention: Brief patient-centered HIV risk-reduction counseling with a rapid HIV test
Number of subjects: 5012

Group type: COMPARATOR
Intervention: Rapid HIV test with information only (control group)
Number of subjects: 5012
Study: 21765964

Group type: EXPERIMENTAL
Intervention: Mass treatment with anti-filarial drugs (4 annual administrations)
Number of subjects: 16480

Group type: EXPERIMENTAL
Intervention: Mass treatment with anti-filarial drugs in communities with high pre-treatment transmission (224-742 infective bites/person/year)
Number of subjects: 16480

Group type: EXPERIMENTAL
Intervention: Mass treatment with anti-filarial drugs in communities with moderate pre-treatment transmission (24-167 infective bites/person/year)
Number of subjects: 16480
Study: 19478342

Group type: EXPERIMENTAL
Intervention: Protein supplement provided in the morning and evening (n = 13)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Protein supplement provided immediately before and immediately after workouts (n = 13)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (n = 7) with no protein or other nutritional supplement
Number of subjects: 33
Study: 17373187

Group type: EXPERIMENTAL
Intervention: Biologic agents
Number of subjects: 0
Study: 15196600

Group type: EXPERIMENTAL
Intervention: Lithium augmentation of nortriptyline
Number of subjects: 92
Study: 11282251

Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clomipramine 100 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9198080

Group type: EXPERIMENTAL
Intervention: Liquid non‐caloric meal (5 mL water kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Second meal given within one hour after the first meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phasic 3 cycles per minute (CPM) signal observed after a meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phasic 3 CPM signal during fasting state
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Measurement of gastric emptying pattern with epigastric impedance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epigastric impedance measurement
Number of subjects: 30
Study: 8471370

Group type: EXPERIMENTAL
Intervention: re‐IVRA
Number of subjects: 120

Group type: COMPARATOR
Intervention: IVRA
Number of subjects: 120
Study: 4042306

Group type: EXPERIMENTAL
Intervention: naloxone (10 mg iv followed by a continuous infusion of 10 mg/hr)
Number of subjects: 12

Group type: COMPARATOR
Intervention: saline
Number of subjects: 12
Study: 28939661

Group type: EXPERIMENTAL
Intervention: Safe sleep health education intervention delivered as part of the 2-week WCV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-matched control group receiving a scald burn prevention intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care group
Number of subjects: 0
Study: 29932345

Group type: EXPERIMENTAL
Intervention: Nitric oxide
Number of subjects: 244
Study: 27265121

Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral Block (TPVB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Epidural Anesthesia (EA)
Number of subjects: 100
Study: 25636293

Group type: EXPERIMENTAL
Intervention: Fluoride vanish, semi‐annual application
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Resin sealant, single placement
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Fluoride foam, semi‐annual application
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Placebo control with oral hygiene instruction
Number of subjects: 1016
Study: 22290354

Group type: EXPERIMENTAL
Intervention: Cell saver group
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study: 20095977

Group type: EXPERIMENTAL
Intervention: Triathletes
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 78
Study: 18528294

Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate-pulsed dendritic cell (DC) vaccine administered every other week for 3 doses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate-pulsed DC vaccine followed by low-dose IL-2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate-pulsed DC vaccine followed by high-dose IL-2
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 24
Study: 15912460

Group type: EXPERIMENTAL
Intervention: IOL-Master (Zeiss)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Keratometer (Zeiss)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Corneal topograph (EyeSys Technologies)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clinical history method (chm)
Number of subjects: 34
Study: 14629807

Group type: EXPERIMENTAL
Intervention: Point-of-care urine test for smoking with visual and numerical feedback
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Point-of-care urine test for smoking
Number of subjects: 856

Group type: COMPARATOR
Intervention: Control group received anti-smoking counselling as part of routine care
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Combined smoking test results at 36 weeks
Number of subjects: 856
Study: 10690134

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg kg‐1
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rapacuronium 1.5 mg kg‐1 with three incremental doses of 0.5 mg kg‐1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Neostigmine vs Edrophonium after three incremental doses of rapacuronium
Number of subjects: 70
Study: 8701899

Group type: EXPERIMENTAL
Intervention: OPC-18790
Number of subjects: 21

Group type: COMPARATOR
Intervention: dobutamine
Number of subjects: 21
Study: 8445303

Group type: EXPERIMENTAL
Intervention: Head dressing
Number of subjects: 100

Group type: COMPARATOR
Intervention: No head dressing
Number of subjects: 100
Study: 3080114

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine derived from yeast
Number of subjects: 50

Group type: COMPARATOR
Intervention: Plasma derived hepatitis B vaccine
Number of subjects: 50
Study: 30359369

Group type: EXPERIMENTAL
Intervention: Social stress
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physical stress
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of social and physical stress
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 100
Study: 26732694

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope
Number of subjects: 100
Study: 23374977

Group type: EXPERIMENTAL
Intervention: Intermediate care for 48 hours
Number of subjects: 400

Group type: COMPARATOR
Intervention: Surgical ward care
Number of subjects: 400
Study: 20656725

Group type: EXPERIMENTAL
Intervention: Single session counselling
Number of subjects: 1339

Group type: COMPARATOR
Intervention: Non-counselling
Number of subjects: 1339
Study: 19761115

Group type: EXPERIMENTAL
Intervention: Spoon-needle cluster (SNO) treatment
Number of subjects: 164

Group type: COMPARATOR
Intervention: Filiform-needle cluster (FNC) treatment
Number of subjects: 164
Study: 17174593

Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure (0.15 ppm to 1.0 ppm)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control 1 (buccal smears prepared 1 week before the study)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control 2 (buccal smears at the start of the study before first exposure)
Number of subjects: 21
Study: 15328078

Group type: EXPERIMENTAL
Intervention: Eritoran (E5564) 500 microg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eritoran (E5564) 2,000 microg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eritoran (E5564) 3,500 microg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eritoran (E5564) 500 to 3,500 microg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eritoran (E5564)
Number of subjects: 0
Study: 12241627

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate (CB) 0.05% cream
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hydrocortisone (HC) 1% cream
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study: 9273824

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 1594

Group type: COMPARATOR
Intervention: Control (other antihypertensive agents)
Number of subjects: 1594
Study: 8508282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 3578745

Group type: EXPERIMENTAL
Intervention: Potassium and sodium chloride (group A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Potassium aspartate (group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Balanced solution of electrolytes and trace metals (Inzolen) with aspartate as the anion (group C)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Trace metals supplementation (group C)
Number of subjects: 75
Study: 28118307

Group type: EXPERIMENTAL
Intervention: High-Intensity Power Training (HIPT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Traditional Power Training (TPT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 29
Study: 27159758

Group type: EXPERIMENTAL
Intervention: Uterosacral suspension
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Sacrospinous suspension
Number of subjects: 374

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 374
Study: 24477778

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks or 420 mg every month
Number of subjects: 300

Group type: COMPARATOR
Intervention: Ezetimibe (control)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 300
Study: 23192752

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral self-help intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (online psychoeducative information modules)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 196
Study: 21197850

Group type: EXPERIMENTAL
Intervention: 75% O2:21% N2:4% Ar
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 56% O2:42% N2:2% Ar
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 10
Study: 18427501

Group type: EXPERIMENTAL
Intervention: Tianeptine (coaxil) - serotonin reuptake enhancer
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sertraline (zofort) - selective serotonin reuptake inhibitor
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 43
Study: 16161725

Group type: EXPERIMENTAL
Intervention: Voucher-based contingency management for substance abuse treatment (criminal justice involved)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voucher-based contingency management for substance abuse treatment (non-criminal justice involved)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Voucher-based contingency management (both groups)
Number of subjects: 0
Study: 14525573

Group type: EXPERIMENTAL
Intervention: Patent blue dye (PB)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Triple modality (TM)
Number of subjects: 104
Study: 11252342

Group type: EXPERIMENTAL
Intervention: Ceftazidime 6 g/day by continuous infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ceftazidime bolus dosing (2 g 8 hourly)
Number of subjects: 18
Study: 8696250

Group type: EXPERIMENTAL
Intervention: Pre-test cigarette
Number of subjects: 20

Group type: COMPARATOR
Intervention: No pre-test cigarette
Number of subjects: 20
Study: 1835276

Group type: EXPERIMENTAL
Intervention: Aspirin (a nonspecific inhibitor of thromboxane synthesis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulotroban (a specific thromboxane receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6820183

Group type: EXPERIMENTAL
Intervention: Diabetic diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Average Danish food
Number of subjects: 10
Study: 31939063

Group type: EXPERIMENTAL
Intervention: PF‐SZ‐IFX (biosimilar group)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: IFX‐EU (week 30 switch group)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: IFX‐EU (week 54 switch group)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: PF‐SZ‐IFX
Number of subjects: 650
Study: 31521942

Group type: EXPERIMENTAL
Intervention: Vocational Cognitive Ability Training by the Japanese Cognitive Rehabilitation Program for Schizophrenia (VCAT‐J)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Standard treatment plus VCAT‐J
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard treatment (TAU)
Number of subjects: 31
Study: 28726512

Group type: EXPERIMENTAL
Intervention: Higher total HMO concentration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sialylated HMOs
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Non-fucosylated/non-sialylated HMOs
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fucosylated HMOs
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fucosylated/sialylated HMOs
Number of subjects: 11
Study: 24965958

Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Body weight‐supported overground training
Number of subjects: 16
Study: 24389401

Group type: EXPERIMENTAL
Intervention: ALND surgery
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: SLNB surgery
Number of subjects: 391

Group type: COMPARATOR
Intervention: Affected upper limb (ALND)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control upper limb (unaffected)
Number of subjects: 391
Study: 22639823

Group type: EXPERIMENTAL
Intervention: MSI/FM
Number of subjects: 43

Group type: COMPARATOR
Intervention: RME/FM
Number of subjects: 43
Study: 19129355

Group type: EXPERIMENTAL
Intervention: Deep transthecal injection
Number of subjects: 15

Group type: COMPARATOR
Intervention: Subcutaneous injection
Number of subjects: 15

Group type: COMPARATOR
Intervention: Traditional transthecal injection
Number of subjects: 15
Study: 17761317

Group type: EXPERIMENTAL
Intervention: Augmented tendon repair with plantaris tendon (group 1, n=16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: End-to-end suturing technique (group 2, n=14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: End-to-end suturing technique (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: End-to-end suturing technique
Number of subjects: 30
Study: 15218710

Group type: EXPERIMENTAL
Intervention: Colgate Simply White Clear Whitening Gel, three times daily, 30-second air-drying and 30 minutes without eating/drinking
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Colgate Simply White Clear Whitening Gel, four times daily, 30-second air-drying and 30 minutes without eating/drinking
Number of subjects: 120

Group type: COMPARATOR
Intervention: Colgate Simply White Clear Whitening Gel, twice-daily, no air-drying, and 15 minutes without eating/drinking
Number of subjects: 120
Study: 12210460

Group type: EXPERIMENTAL
Intervention: Renal sonography
Number of subjects: 40
Study: 9797080

Group type: EXPERIMENTAL
Intervention: G‐CSF 5 microg/kg per day subcutaneously starting 2 days after S‐HAM treatment
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 68
Study: 7893090

Group type: EXPERIMENTAL
Intervention: Ticarcillin/clavulanate
Number of subjects: 993

Group type: COMPARATOR
Intervention: Clindamycin/gentamicin (without ampicillin)
Number of subjects: 993

Group type: COMPARATOR
Intervention: Clindamycin/gentamicin (with ampicillin)
Number of subjects: 993
Study: 2676877

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 37.5 mg immediate release
Number of subjects: 6
Study: 371318

Group type: EXPERIMENTAL
Intervention: 24 hours of preoperative antibiotic bowel preparation (gentamicin + vancomycin + mycostatin)
Number of subjects: 83

Group type: COMPARATOR
Intervention: 60 hours of preoperative antibiotic bowel preparation (gentamicin + vancomycin + mycostatin)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Long duration operations
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Infected wounds
Number of subjects: 83
Study: 31299919

Group type: EXPERIMENTAL
Intervention: Extended hours haemodialysis (≥24 h/week)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional haemodialysis (≤18 h/week)
Number of subjects: 200
Study: 27859427

Group type: EXPERIMENTAL
Intervention: Citrate HDF (heparin free)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acetate HDF (routine dose of heparin)
Number of subjects: 10
Study: 26383152

Group type: EXPERIMENTAL
Intervention: SB742457 (3 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SB742457 (15 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SB742457 (35 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SB742457 (3, 15, and 35 mg/d)
Number of subjects: 0
Study: 24136111

Group type: EXPERIMENTAL
Intervention: 8 h sitting interrupted with hourly, 8-min moderate-intensity cycling exercise bouts
Number of subjects: 11

Group type: COMPARATOR
Intervention: 8 h prolonged sitting
Number of subjects: 11
Study: 21214349

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) applied using a vibratory platform (35 Hz, 5 mm peak to peak) for 60 seconds before eccentric exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no vibration applied)
Number of subjects: 32
Study: 18644546

Group type: EXPERIMENTAL
Intervention: SBHC users
Number of subjects: 579

Group type: COMPARATOR
Intervention: Comparison school group
Number of subjects: 579
Study: 16248986

Group type: COMPARATOR
Intervention: Aprepitant 160 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Aprepitant 80 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 13679549

Group type: EXPERIMENTAL
Intervention: Combined diltiazem and aspirin/ticlopidine therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Aspirin/ticlopidine therapy alone
Number of subjects: 35
Study: 10896877

Group type: EXPERIMENTAL
Intervention: High-intensity intermittent bicycle training for 5 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 8967303

Group type: EXPERIMENTAL
Intervention: Carbohydrate deficient transferrin (CDT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDT/Tft ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDT and transferrin ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGA hepatic index
Number of subjects: 0
Study: 1420752

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d. plus Pirenzepine 50 mg b.d.
Number of subjects: 157

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d. plus Placebo (Control)
Number of subjects: 157
Study: 3882739

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Exogenous GnRH
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Clomiphene
Number of subjects: 1
Study: 30465187

Group type: EXPERIMENTAL
Intervention: Portal vein occlusion (PVO)
Number of subjects: 48
Study: 30004615

Group type: EXPERIMENTAL
Intervention: Xenon-augmented sevoflurane anesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no anesthesia)
Number of subjects: 40
Study: 27252245

Group type: EXPERIMENTAL
Intervention: Healthlines service (alongside usual care)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 641
Study: 25183313

Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated school uniforms (ISUs)
Number of subjects: 321
Study: 22649265

Group type: EXPERIMENTAL
Intervention: 140 g/d of lipid-based nutrient supplements (LNS)
Number of subjects: 2121

Group type: COMPARATOR
Intervention: No lipid-based nutrient supplements (LNS)
Number of subjects: 2121